GDF5 is involved in synovial joint development, maintenance and repair, and the rs143383 C/T single nucleotide polymorphism (SNP) located in the 5 ′ UTR of GDF5 is associated, at the genome-wide significance level, with osteoarthritis susceptibility, and with other musculoskeletal phenotypes including height, congenital hip dysplasia and Achilles tendinopathy. There is a significant reduction in the expression of the diseaseassociated T allele relative to the C allele in synovial joint tissues, an effect influenced by a second SNP (rs143384, C/T) also within the 5 ′ UTR. The differential allelic expression (DAE) imbalance of the C and T alleles of rs143383 varies intra-and inter-individually, suggesting that DAE may be modulated epigenetically. The C alleles of both SNPs form CpG dinucleotides that are potentially amenable to regulation by methylation. Here, we have examined whether DNA methylation regulates GDF5 expression and the allelic imbalance caused by rs143383. We observed methylation of the GDF5 promoter and 5 ′ UTR in cell lines and joint tissues, with demethylation correlating with increased GDF5 expression. The CpG sites created by the C alleles at rs143383 and rs143384 were variably methylated, and treatment of a heterozygous cell line with a demethylating agent further increased the allelic expression imbalance between the C and T alleles. This demonstrates that the genetic effect of the rs143383 SNP on GDF5 expression is modulated epigenetically by DNA methylation. The variability in DAE of rs143383 is therefore partly accounted for by differences in DNA methylation that could influence the penetrance of this allele in susceptibility to common musculoskeletal diseases.
INTRODUCTION
Osteoarthritis (OA) is a universal chronic musculoskeletal disease that is characterized by the progressive destruction of articular cartilage, synovial inflammation and bone remodelling leading to pain and loss of joint function, with knee, hip, hand and spine joints being most commonly affected. OA affects over 50% of people over the age of 65 regardless of sex or ethnicity (1) , and is the leading cause of chronic disability in the UK, affecting 8 million people. Several genes have been identified that harbour polymorphisms associated with OA susceptibility. The most compelling association is with the rs143383 single nucleotide polymorphism (SNP) located in the 5 ′ UTR of the Growth Differentiation Factor 5 (GDF5) gene (2 -9) .
GDF5 is a member of the transforming growth factor b (TGFb) superfamily and is involved in the maintenance and repair of synovial joints (10) , as well as chondrogenesis and chondrocyte proliferation (11) (12) (13) . GDF5 is essential for normal skeletal, bone and joint development (14) , and mutations in GDF5 underlie several rare skeletal disorders including Acromesomelic Dysplasia, Hunter -Thompson type (15) , Chondrodysplasia, Grebe type (16) , Brachydactyly type A2 (17) and type C (18) and DuPan syndrome (19) . The * To whom correspondence should be addressed. Tel: +44 1912227020; Fax: +44 1912225455; Email: louise.reynard@ncl.ac.uk # The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
rs143383 C to T SNP in the 5
′ UTR of GDF5 is associated with increased susceptibility to OA in both Asian and European populations (2) (3) (4) (5) (6) 8) . This SNP also associates with other musculoskeletal phenotypes including fracture incidence and hip-axis length (7) , congenital hip dysplasia (20, 21) , lumbar disc degeneration (22) and Achilles tendinopathy (23, 24) . rs143383 is itself functional and exerts a joint-wide effect on GDF5 expression, causing a significant reduction in the expression of the disease-associated T allele relative to the C allele in cartilage and other joint tissues (25) , a phenomenon known as differential allelic expression (DAE). This suggests that even a slight reduction in GDF5 expression in synovial joints increases the risk of developing OA and other musculoskeletal disorders, and women homozygous for the C allele at rs143383 have a 28% lower risk of developing knee OA compared with those homozygous for the T allele (7) . The transcriptional effect of rs143383 SNP is dependent on a second C to T SNP in the 5 ′ UTR of GDF5, rs143384, with decreased expression of the T allele of rs143383 only observed in individuals that are compound heterozygous for both SNPs. The T alleles of rs143383 and rs143384 are also associated with reduced height (7, 26, 27) , implying that these SNPs have an effect on GDF5 expression during skeletal development as well as in adult life.
Mouse models have also shed light on the role of GDF5 in skeletogenesis and joint maintenance and function, and these models are highly relevant to the human genetic studies. The brachypodism mouse is homozygous for a frame-shift mutation of Gdf5 that causes a premature termination codon, resulting in a null allele. These mice have a number of defects including a shortened appendicular skeleton, a decrease in the length of the limb long bones, and abnormalities of the intra-articular ligaments. These abnormalities clearly demonstrate an important role for GDF5 in normal development (14, 28, 29) . A mouse that carries only one copy of the brachypodism null allele does not show such developmental abnormalities but does show an increased likelihood to develop an OA phenotype when challenged (30) . This model, which from a molecular genetics perspective somewhat mimics the effect of SNP rs143383 in human OA, confirms the importance of maintaining adequate levels of GDF5 for normal joint function and emphasizes again the detrimental effects of quantitative alterations in GDF5 on joint maintenance.
Several studies have indicated that loss of normal epigenetic gene regulation may play a role in the pathogenesis of OA, with chondrocytes from the cartilage of OA patients having disrupted patterns of DNA methylation associated with abnormal gene expression (31) (32) (33) (34) . The DAE imbalance between the C and T alleles of rs143383 varies between joint tissues from a single individual and between individuals of the same haplotype (25) , suggesting that the genetic effect of this SNP on GDF5 transcription may be modulated epigenetically. When the OA-protective C alleles are present at the rs143383 and rs143383 SNPs, they form CpG dinucleotides which are potentially amenable to regulation by DNA methylation. We therefore decided to investigate whether DNA methylation plays a role in regulating GDF5 expression overall and at an allelic level.
In this study, we show that the GDF5 promoter and 5 ′ UTR are subject to DNA methylation in both human cell lines and joint tissues. We demonstrate that GDF5 is significantly upregulated in cell lines after exposure to a demethylating agent and that methylation of the proximal promoter and 5
′ UTR results in a decrease in the transcriptional activity of these regions. We also find that the CpG sites formed by the C alleles of rs143383 and rs143384 are methylated in cell lines and joint tissues, and that demethylation of several CpG sites within the 5 ′ UTR is associated with increased expression of the C allele of rs143383 relative to the T allele. Together, these data suggest that DNA methylation is involved in the transcriptional regulation of GDF5 in joint tissues and that the functional effect of the OA susceptibility SNP rs143383 is modulated epigenetically by DNA methylation.
RESULTS

The promoter and 5
′ UTR of GDF5 are methylated in cell lines and joint tissues
To identify putative methylation loci, we searched the genomic region extending 1.5 kb upstream of the GDF5 transcription start site (TSS) and 5
′ UTR for the presence of CpG sites in addition to the two sites at +41 and +268 bp that are created by the presence of the C allele at rs143383 and rs143384. A putative CpG island containing nine CpG sites was identified between 21344 and 21209 bp upstream of the TSS using the MethPrimer online tool (35) . Three additional regions containing clusters of CpG dinucleotides are present downstream of the CpG island (21081 to 2755 bp, seven sites; proximal promoter, 2453 to 2153 bp, seven sites; 5 ′ UTR, +9 to +301 bp, eight sites excluding those created by the C alleles of rs143383 and rs143384). The methylation status of each CpG site within these four regions was examined by sequencing of bisulphatetreated genomic DNA. Initial methylation analysis was performed on four human cell lines that express different levels of GDF5 (Fig. 1A and B) ; highly expressing CH8 articular chondrocytes, SW1353 chondrosarcoma cells that express medium levels of GDF5, the low expressing SaOS-2 osteosarcoma cells and COLO205 colon adenocarcinoma cells which do not express GDF5 (Fig. 1A) .
The two CpG sites upstream of the CpG island are hypermethylated (.80% methylation) in all four cell lines studied, whereas the two sites immediately downstream of the island are largely unmethylated (,8% methylation; Fig. 1B After examining the GDF5 CpG island and proximal promoter in cell lines, we then looked at the methylation of these regions in GDF5-expressing synovial joint tissues from an OA patient and in peripheral blood, which does not express GDF5 (Fig. 1C and D) . The two sites immediately upstream and downstream of the CpG island were hypermethylated and hypomethylated, respectively, with variable methylation observed at sites within the CpG island itself, similar to the methylation pattern of this region observed in cell lines. CpG sites within the CpG island and proximal promoter were hypermethylated in the peripheral blood DNA, with significantly lower methylation levels within these two regions in joint tissues (e.g. 87.3% proximal promoter methylation in blood compared with 30.1 -61.5% methylation in joint tissues, P , 0.01). Methylation levels of individual CpG sites vary between the synovial joint tissues taken from the same patient.
Both CpG island sites (21305 and 21300) that are differentially methylated in cell lines also have variable methylation in blood and joint tissues, with additional sites within the CpG island showing variation in the tissues. Four sites within the proximal promoter (2338, 2323, 2312, 2221 bp) show significant variability in methylation status in both cell lines and human tissues, and these sites are conserved in other placental mammals (Supplementary Material, Fig. S1 ), suggesting they may be important for the epigenetic regulation of GDF5 by DNA methylation. This is supported by the observation that methylation levels of the proximal promoter region correlate with gene expression in cell lines.
GDF5 expression is upregulated in human cell lines after exposure to the demethylating agent 5-Aza-2 ′ deoxycytidine
To further investigate the role of DNA methylation in the regulation of GDF5 expression, we examined the effect the demethylating agent 5-Aza-2 ′ deoxycytidine (AZA) had on GDF5 transcript levels. AZA is a cytidine analogue that is incorporated into the DNA during replication and sequesters the activity of DNA methyltransferase enzymes, resulting in passive demethylation over several cell divisions. CH8, SaOS-2, COLO205 cells and the SW872 liposarcoma human cell line (which is compound heterozygous for the rs143383 and rs143383 SNPs), were treated with two concentrations 
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of AZA for three population doublings. GDF5 expression and methylation of the CpG island and 5 ′ UTR were assessed by qRT -PCR and bisulphite pyrosequencing, respectively, and the levels compared between treated and untreated cells (Fig. 2) . In all four cell lines, GDF5 transcription was significantly upregulated in cells exposed to AZA relative to control cells, with a 1.6-and 1.8-fold increase in GDF5 mRNA in CH8 cells cultured with 0.5 and 1 mM AZA, respectively (P , 0.005 and P , 0.001, Student's t-test; Fig. 2A ). GDF5 was upregulated between 7.3-and 8.7-fold in AZA-treated SaOS-2 cells (P , 0.01 and P , 0.005; Fig. 2B ), while GDF5 was not expressed in control COLO205 cells but was induced in cells exposed to AZA (Fig. 2D ). SW872 cells cultured with AZA had significantly increased GDF5 expression (2.6-fold with 0.25 mM and 2.5-fold with 0.5 mM, P , 0.001; Fig. 2C ).
The increased expression of GDF5 in cells treated with AZA was accompanied by demethylation of the GDF5 CpG island and 5
′ UTR with both concentrations of AZA relative to control cells. For example, overall methylation of the CpG island decreased from 79.4% in untreated CH8 cells to 33.9 and 40.2% in 0.5 and 1 mM AZA-treated CH8 cells, respectively ( Fig. 2A) , and from 51.4 to 31.2% (0.25 mM AZA) and 35% (0.5 mM AZA) in COLO205 cells (Fig. 2D) , while the methylation of the 5 ′ UTR was reduced from 74.6 to 48.4% (0.5 mM AZA) and 66.6% (1 mM AZA) in SaOS-2 cells (Fig. 2B ). This demethylation may account, at least in part for the increased expression of GDF5 observed in cells exposed to AZA. No specific CpG site within the CpG island or the 5 ′ UTR was consistently demethylated in all four cell lines studied, suggesting that the overall methylation level of the GDF5 promoter rather than the methylation status of one particular CpG site may be important in regulating GDF5 expression.
DNA methylation results in a significant reduction in the transcriptional activity of the CpG island, proximal promoter and 5 ′ UTR of GDF5
The above results demonstrate that AZA-induced demethylation is associated with increased GDF5 expression levels in all four cell lines examined. However, this upregulation may be due to changes in the expression of activators and repressors of GDF5 rather than demethylation of the GDF5 locus. We decided to directly investigate the effect of DNA methylation on the activity of the GDF5 CpG island, proximal promoter and 5 ′ UTR fused to a luciferase reporter gene using in vitro methylation followed by transient transfection (Fig. 3, Supplementary Material, Fig. S2 ). Many commercially available luciferase reporter vectors contain CpG sites within their backbone that can repress activity of the luciferase reporter gene when methylated (36) , making it difficult to discriminate the effect of methylation of inserted promoter on luciferase activity from that of the methylated vector. To circumvent this issue, we decided to use the CpG-free pCpGL luciferase vector, whose basal luciferase activity is unchanged by methylation (36) . The regions encompassing the GDF5 CpG island, proximal promoter and 5 ′ UTR were cloned into the pCpGL vector and all the CpG sites within the inserted DNA were methylated using the SssI DNA methyltransferase. Methylated and non-methylated control pCpGL-CpG island, pCpGL-proximal promoter and pCpGL-5 ′ UTR vectors were transfected into SW1353 chondrosarcoma cells (Fig. 3) and SW872 liposarcoma cells (Supplementary Material, Fig. S2 ) and their luciferase activities measured. The CpG island region had very low levels of reporter activity in both cell lines relative to the proximal promoter and 5 ′ UTR, with the methylated pCpGL-CpG island construct having significantly reduced luciferase activity compared with the unmethylated control (a 30% decrease in SW1353 cells and 19% decrease in SW872 cells, P , 0.001 and P , 0.01, respectively, Student's t-test). CpG methylation also significantly decreased the activity of the proximal promoter, with a 7.9-fold reduction in luciferase expression in SW1353 cells (P , 0.0001) and a 3.1-fold reduction in SW872 cells (P ¼ 0.0001) relative to the unmethylated control. In addition, the promoter activity of the unmethylated 5 ′ UTR plasmid was significantly higher in both cell lines compared with the methylated 5 ′ UTR plasmid. This affect was independent of the allele present at the rs143383 and rs14484 SNPs, with a 1.7-fold increase (P ¼ 0.00044) in unmethylated versus methylated promoter activity when the C allele was present and a 1.6-fold increase (P ¼ 0.0062) with the T allele in SW1353 cells. Together, these data indicate that DNA methylation of the GDF5 promoter and 5 ′ UTR directly affects the transcriptional activity of these regions.
The CpG sites created by the C alleles at rs143383 and rs143384 are methylated in cell lines and joint tissues
Analysis of human cell lines demonstrated that all CpG sites within the 5 ′ UTR of GDF5 are methylated to various extents. We decided to further examine cell lines (Fig. 4A ) and joint tissues from OA patients (Fig. 4B ) to see if this is also true for the CpG sites created by the C alleles at rs143383 and rs143384, which have an r 2 of 0.88 (International HapMap Project release 28). The cell lines that we focussed on were SW1353, which is homozygous for the C alleles at rs143383 and rs143384, and SW872 and COLO205, which are heterozygous at both rs143383 and rs143384 (see Supplementary Material, Fig. S3 ). The three patients that we studied are also compound heterozygotes at these two SNPs. The rs143383 CpG site was methylated at low levels in the SW1353 (17.6%), SW872 (15.8%) and COLO205 (22.1%) cell lines (Fig. 4A) . The C allele of rs143384 was also methylated in these cell lines, although the level of methylation was more varied than at rs143383 (88.9% in SW1353 cells, 21.1% in SW872 cells and 22% in COLO205 cells). Both rs143383 and rs143384 CpG sites were methylated in synovial joint tissues, although the level of methylation varied between the three individuals and also between different tissues from the same individual. We observed a trend for the C allele of rs143384 to have a higher level of methylation than the C allele at rs134483 within the same cell line or joint tissue.
The DAE of rs143383 is increased after AZA treatment
We hypothesized that the methylation of rs143383 and rs143384 CpG sites may contribute to the DAE of the C and T alleles of rs143383. In order to investigate this possibility, we analysed the effect that AZA treatment had on the DAE of rs143383. Of the 14 cell lines available to us, only one expresses GDF5 and is heterozygous for both rs143383 and rs143384 SNPs (Supplementary Material, Fig. S3 ). SW872 cells were exposed to AZA for three population doublings and the relative amount of GDF5 expression from the T and C alleles of rs143383 was measured using allele-specific qRT -PCR primers (Fig. 5A) . In control cells, there is a DAE imbalance of 1.11 between the C and T alleles, i.e. for every T transcript present, there are 1.11 C transcripts. The difference in allelic expression is significantly increased after exposure to AZA, with a DAE of 2.24 in cells treated with 0.25 mM AZA (P ¼ 0.03, Student's t-test) and a DAE of 2.50 with 0.5 mM AZA (P ¼ 0.025). We examined ′ UTR constructs, the insert has either a C allele at both rs143383 and rs143384 or a T allele at both SNPs. pCpGL vectors were co-transfected with the unmethylated pRL-TK Renilla plasmid to normalize for transfection efficiency. Data shown are the mean + SD of three independent experiments, with five replicates per construct, * * * P , 0.001, Student's t-test.
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whether the increased DAE was associated with demethylation of the rs143383 and/or rs143384 CpG sites by comparing methylation levels in control and AZA-treated cells (Fig. 5B) . There was no difference in methylation of the C alleles of rs143383 and rs143384 between AZA-treated and untreated cells. However, we observed significant demethylation of CpG sites at positions +37 (located 3 bp upstream of rs143383), +96, +106 and +147 in cells treated with both concentrations of AZA and at +210 in 0.25 mM treated cells (P , 0.01, Fisher's exact test). All five demethylated CpG sites show significant variability in methylation status in cell lines (Fig. 1B) , while four of the five sites are differentially methylated in joint tissues (Fig. 4B ). All five sites are conserved within placental mammals (Supplementary Material, Fig. S4 ), implying that they may have important functional roles. Together, these data indicate that genetic as well as epigenetic factors, involving DNA methylation, contribute to the DAE of GDF5 SNP rs143383.
DISCUSSION
The initial aim of this study was to investigate whether the OA susceptibility gene GDF5 is regulated epigenetically by DNA methylation. Bisulphite sequencing of DNA from four human cell lines, peripheral blood and synovial joint tissues demonstrated that the putative CpG island, proximal promoter and 5 ′ UTR of GDF5 are subject to DNA methylation, with the combined methylation levels of these regions correlating with GDF5 expression. We identified several highly conserved CpG dinucleotides upstream of the TSS and within the 5 ′ UTR that had variable levels of methylation in both cell lines and human tissues; these sites are located within a region known to have promoter activity (37) . Taken together, these data suggest that GDF5 expression is regulated by DNA methylation. ′ UTR methylation in synovial joint tissues from (i) a 60-year-old male with hip OA, (ii) a 75-year-old male with OA of the knee and (iii) a 72-year-old male with hip OA. All three individuals underwent elective joint replacement surgery and are compound heterozygotes for the rs143383 and rs143384 SNPs. Bisulphite DNA was PCR amplified and between 10 and 20 unique clones were sequenced per cell line or joint tissue. Grey bars represent CpG sites that were not present within the sequenced clone. The CpG sites created by the presence of the C alleles at rs143383 and rs143384 (highlighted) are subject to methylation, although the levels of methylation at these sites vary between the cell lines and joint tissues. We next examined the effect that an inhibitor of DNA methylation had on GDF5 expression. Transcription of GDF5 was significantly upregulated in cell lines after treatment with the demethylating agent AZA and was induced in cells where the gene is normally silent. GDF5 upregulation was associated with demethylation of the CpG island and of the 5 ′ UTR, although no specific sites within these regions were consistently demethylated in all four cell lines assayed. This suggests that the overall methylation levels of the GDF5 locus may be important in regulating this gene rather than the methylation status of specific CpG dinucleotides. Furthermore, we found that in vitro methylation of the CpG island caused a significant reduction in its promoter activity as assayed by luciferase reporter activity. Methylation of the proximal promoter and 5
′ UTR also resulted in a significant decrease in the transcriptional activity of these regions, which have a relatively low density of CpG sites, even though gene repression by DNA methylation is thought to require a high density of CpG sites (38) .
Using the criteria of Weber et al. (38) , the CpG island located between 21344 and 21209 bp upstream of the GDF5 TSS is classified as a 'weak' CpG island because of its short length (135 bp) and relatively low CG density. We observed high levels of methylation of the GDF5 CpG island in both cell lines and primary human tissue, which is in agreement with previous data demonstrating that weak CpG islands are usually hypermethylated. In addition, the CpG island has very low promoter activity relative to the proximal promoter and 5 ′ UTR in vitro, and is only found in humans and not other mammals. This suggests that the CpG island may not be involved in regulating GDF5 expression, although we cannot rule out a human specific role for this region in controlling GDF5 activity in vivo.
Analysis of the GDF5 locus in other mammals indicates that the disease-associated T alleles of rs143383 and rs143384 appear to have evolved by the spontaneous deamination of the methylated C allele into a T residue in the human germline. The CpG sites formed by the C alleles of both SNPs are subject to methylation in cell lines and human joint tissues, with higher levels of methylation observed at rs143384 than at rs143383. There is considerable variation in methylation level of both SNPs in joint tissues from the same individual even though the tissues are all of mesenchymal origin, and this variability could be responsible for the intra-individual differences in DAE observed previously (25) . We also observed that AZA induced an increase in the transcription of the C allele of rs143383 relative to the T allele in the heterozygous SW872 cell line, resulting in a significant increase in the DAE. This was associated with demethylation of the GDF5 5 ′ UTR, with a consistent and significant decrease in methylation levels of CpG sites at +37 (three bases upstream of rs143383), +96, +106 and +147 bp. Demethylation of these CpG sites may affect binding of repressive methyl-binding proteins or of transcriptional regulators of GDF5. Our data suggest that changes in the methylation status of the GDF5 5 ′ UTR in response to environmental factors or with aging may lead to changes in the level DAE within that tissue. As the small but persistent decrease in GDF5 expression throughout life is thought to be responsible for the increased susceptibility to OA mediated by the T allele of rs143383, such changes in methylation and thus DAE may affect the OA development, progression and severity. In addition, inter-individual differences in methylation of the 5 ′ UTR may be responsible for the variation in DAE observed in individuals of the same haplotype previously reported (25) . Numerous twin studies have demonstrated that there are significant epigenetic differences between both monozygotic and dizygotic twins that increase with age, potentially explaining the phenotypic discordance in disease phenotypes between twins (39-41). Thus, differences in GDF5 methylation could also explain the incomplete penetrance of the musculoskeletal disorders associated with both rs143383 and rs143384. Further work is required to determine how the methylation status of a specific CpG site or combination of sites within the 5 ′ UTR affects DAE of rs143383 and whether these sites are abnormally methylated in OA joint tissue relative to non-OA joint tissues.
In addition to OA, the rs143383 SNP is associated with several other musculoskeletal conditions, with individuals homozygous for the T allele having an 2-fold increased odds of developing Achilles tendinopathy and a 1.5 increased odds of having congenital dysplasia of the hip (CDH) relative to CT or CC individuals (21, 23) . Investigating the role of DNA methylation in regulating the allelic imbalance of rs143383 and potentially disease penetrance is therefore relevant not only to OA but to several other joint diseases. rs143384 is also associated with CDH (1.7 higher odds for TT individuals relative to CT and CC individuals) (21), as well as to testicular germ cell tumours (TGCT, odds ratio of 1.5) (42) , and this latter association suggests that the effect of the rs143384 polymorphism is not restricted to the musculoskeletal system. No association between rs143383 and TGCT was found, and so the increased susceptibility mediated by rs143384 may be independent of the regulatory effect this SNP has on the DAE of rs143383. In light of our data that GDF5 transcriptional activity is directly regulated by DNA methylation and that the C allele of rs143384 can itself be methylated, it will be interesting to determine if DNA methylation of GDF5 plays a role in the pathogenesis of TGCT.
Global DNA methylation levels decrease with age (43-46) and it has been proposed that one of the mechanisms responsible for the late onset of common human diseases is the age-related loss of normal epigenetic patterns such as methylation (47) . While the role of DNA methylation changes in the pathogenesis of common diseases such as cancer and type 2 diabetes have been widely investigated, few studies have addressed the role of DNA methylation in the development and progression of OA. While there are no differences in the global DNA methylation levels or levels of the DNA methyltransferase enzymes DNMT1 and DNMT3 between OA and normal cartilage (48), several genes have been reported to have altered DNA methylation patterns in OA. Late-stage OA chondrocytes have increased expression of cartilage degrading enzymes including MMP3, MMP9, MMP13 and ADAMTS4, and this is associated with demethylation of specific CpG sites within the promoter of the genes coding for these enzymes (31) (32) (33) . Hypermethylation of genes may also be important in OA, with the age-related decline of BMP7 levels in chondrocytes correlating with increased promoter methylation of BMP7 (49), while increased methylation
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Human Molecular Genetics, 2011, Vol. 20, No. 17 of the SOD2 promoter in OA cartilage is associated with decreased gene expression (34) . However, there is no evidence that the promoter methylation changes in OA chondrocytes contribute to disease initiation, progression or severity, and the methylation changes reported in these studies may be a consequence rather than a cause of altered gene expression. The studies on DNA methylation in OA have so far concentrated on methylation in cartilage and chondrocytes but it is becoming increasing apparent that OA is a disease of the entire joint, and given the intra-individual variability in methylation of the GDF5 locus that we observed, DNA methylation in other joint tissues should be investigated too. Spontaneous deamination of methylated CpG sites in the germline can lead to the emergence of new SNPs, with considerably higher evolutionary loss of CpG dinucleotides occurring in CpG poor promoter regions (which are hypermethylated in the germline) than CG rich regions (which are largely unmethylated) (38) . These deamination events may have occurred several times in the human GDF5 gene, with three of the seven common SNPs and one of the six very rare variants present in European populations appearing to have evolved this way (50) . At least two of these four GDF5 SNPs are associated with common human diseases and it is possible that such germline deamination events may be responsible for the appearance of a number of disease-associated polymorphisms. Our data, coupled with previous observations, indicate that epigenetic mechanisms including DNA methylation are likely to play a role in both the evolution of and functional effects caused by polymorphisms associated with common diseases.
Our findings that DNA methylation regulates overall expression of GDF5 as well as the allelic imbalance of rs143383 is important and suggests that demethylating agents such as Decitabine may potentially be used as joint-targeted therapeutic drugs in the treatment of OA. However, given that these drugs trigger genome-wide demethylation, further work on the role of methylation in OA and effect of demethylating compounds on gene expression and function in synovial tissues is required. Elucidating both the specific CpG sites whose methylation status modulates the DAE of rs143383 and the DNA-binding proteins that mediate this effect may provide GDF5 specific targets for therapeutic intervention in the future.
To conclude, here we show for the first time that DNA methylation is involved in the transcriptional regulation of the OA susceptibility gene GDF5 in human cell lines and joint tissues. Furthermore, we demonstrate that the functional effect of the OA-associated SNP rs143383 on gene expression is modulated by DNA methylation, indicating that genetic and epigenetic factors can work in combination to influence susceptibility to OA and to the susceptibility of other common musculoskeletal phenotypes associated with polymorphism at GDF5.
MATERIALS AND METHODS
DNA methylation analysis
The 1.5 kb region upstream of the GDF5 TSS and the 5 ′ UTR of GDF5 were obtained from Ensembl genome browser and examined for the presence of a CpG island using the MethPrimer online search tool (http://www.urogene.org/methprimer/) (35 ′ ). Genomic DNA (500 ng to 1 mg) was bisulphite treated (which induces chemical modification of unmethylated cytosine residues to uracil but 5-methylcytosine is resistant to this modification) using the EpiTect Bisulfite kit (Qiagen), and the region of interest amplified by PCR using Titanium Taq (Clontech) using PCR conditions previously described (34) . PCR products were purified using the QIAquick gel extraction kit (Qiagen), cloned using the TOPO TA cloning kit (Invitrogen, Paisley, UK) and sequenced until 10-20 unique clones per amplicon were obtained. DNA methylation analysis was performed using BiQ analyser software (http://biq-analyzer.bioinf.mpi-sb.mpg.de/) (51), and only unique clones with over 90% identity to the genomic sequence and a bisulphite conversion rate of 95% or above were included in the analysis. Differentially methylated sites were identified using pair-wise comparisons between the CH8 cell line and SW1353, SaOS-2 and COLO205 cell lines, and between blood and synovial joint tissues (not corrected for the number of tests) using Fisher's exact test.
Pyrosequencing
For more high-throughput analysis of the percentage methylation at individual CpG sites, quantitative bisulphite pyrosequencing was used. PCR primers for pyrosequencing analysis were designed using the Pyrosequencing Assay Design software (Biotage, Sweden) for the CpG island (FP and RP as above with the RP biotinylated, sequencing primer 5
Bisulphite-converted DNA was amplified as earlier, with two PCR replicates per sample, and the biotin-labelled products sequenced using the PyroMark Q96 MD system as described previously (52) . Pyro Q CpG 1.0.6 software was used to exclude samples that did not pass the bisulphite conversion test and to quantify methylation.
Nucleic acid extraction
Synovial joint tissues were obtained from patients undergoing elective total joint replacement (TJR) surgery with the approval Human Molecular Genetics, 2011, Vol. 20, No. 17 3457 of local Ethical Committees and informed donor consent. Peripheral blood was obtained from a 25-year-old male without OA because our ethics did not allow us to collect blood from TJR patients. RNA was extracted from joint tissues using Qiagen RNeasy kit (Qiagen, Crawley, UK) and genomic DNA was purified from the first wash of the RNeasy columns by ethanol precipitation. RNA and DNA were extracted from monolayer cells grown in culture using the Omega EZNA Total DNA/RNA isolation kit (R6731-00; Omega Bio-Tek) following the manufacturer's protocol.
Cell culture and AZA treatment CH8 (human articular chondrocytes), SW872 (human liposarcoma), SaOS-2 (human osteosarcoma) and COLO205 (human colon adenocarcinoma) cell lines were seeded in 75 cm 2 flasks, and allowed to attach overnight. After adhering, cells were cultured in the presence of AZA dissolved in 50% acetic acid for three population doublings with control cultures containing 50% acetic acid only. The most effective concentration of AZA for promoting demethylation without toxicity was assayed for each cell line and SW872 and COLO205 cells were cultured with AZA at a final concentration of 0.25 and 0.5 mM AZA, and CH8 and SaOS-2 cells with 0.5 and 1 mM AZA. Fresh AZA was added to the cultures every 2 days during the time course of the experiment. At the end of each population doubling, cells were washed once in PBS and half of the cells harvested for nucleic acid extraction (discussed earlier).
Real time RT -PCR and DAE analysis
Total RNA (500 ng to 1 mg) was reverse transcribed using the SuperScript First-Strand Synthesis System (Invitrogen) and GDF5 expression assessed by real time RT-PCR (FP 5 ′ -CTGTGATTCCAGGAGTGCAG-3 ′ , RP 5 ′ -ATCCTCTT-CATTGACTCTGCC-3 ′ , probe 5 ′ -CCACGACCATGTCCTC-3 ′ ), with mRNA levels normalized to 18s, GAPDH and HPRT1 housekeeping genes using the calculation 2 2 DCt. DAE of the T and C alleles of rs143383 SNP in SW872 cells was analysed by RT-PCR using allele-specific primers (FP 5 ′ -AGTC AGTTGTGCAGGAGAAAGG-3 ′ , RP 5 ′ -GCAGCTGAAAAT AACTCGTTCTTGAA-3 ′ and probe 5 ′ -AGAAAGCCAC CGCC-3 ′ ). Three independent experiments were performed with five DNA replicates and five cDNA replicates per sample, and cDNA allelic ratio normalized to the genomic DNA ratio (representing the 1:1 ratio between alleles). Statistical analysis was performed using the Student's 2-tailed t-test. 
Transient transfection assays with pCpGL vectors
